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Background: Contribution of resorption to bone 
anabolism by PTH receptor signaling in 
osteocytes is unknown. 
Results: Pharmacologic/genetic approaches 
demonstrated that remodeling- or modeling-
based bone formation differentially operate in 
specific surfaces.   
Conclusion: Resorption is critical for anabolism 
in periosteal/endocortical bone surfaces, but 
tempers bone gain in cancellous bone. 
Significance: Targeting bone compartment-
specific actions of PTH receptor signaling could 
enhance the therapeutic potential of the pathway. 
ABSTRACT 
The contribution of remodeling-based bone 
formation coupled to osteoclast activity versus 
modeling-based bone formation that occurs 
independently of resorption, to the anabolic 
effect of PTH remains unclear. We addressed 
this question using transgenic mice with 
activated PTH receptor signaling in 
osteocytes that exhibit increased bone mass 
and remodeling, recognized skeletal effects of 
PTH elevation. Direct inhibition of bone 
formation was accomplished genetically by 
overexpressing the Wnt antagonist 
Sost/sclerostin; and resorption-dependent 
bone formation was inhibited 
pharmacologically with the bisphosphonate 
alendronate. We found that bone formation 
induced by osteocytic PTH receptor signaling 
on the periosteal surface depends on Wnt 
signaling but not on resorption. In contrast, 
bone formation on the endocortical surface 
results from a combination of Wnt-driven 
increased osteoblast number and resorption-
dependent osteoblast activity. Moreover, 
elevated osteoclasts and intracortical/calvarial 
porosity is exacerbated by overexpressing 
Sost and reversed by blocking resorption. 
Furthermore, increased cancellous bone is 
abolished by Wnt inhibition but further 
increased by blocking resorption. Thus, 
resorption induced by PTH receptor signaling 
in osteocytes is critical for full anabolism in 
cortical bone, but tempers bone gain in 
cancellous bone. Dissecting underlying 
mechanisms of PTH receptor signaling would 
allow targeting actions in different bone 
compartments, enhancing the therapeutic 
potential of the pathway.  
Parathyroid hormone (PTH)2 has profound 
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effects on the skeleton, and its elevation in the 
circulation can generate both catabolic and 
anabolic effects on bone depending on the 
temporal profile of its increase. Chronic excess 
of PTH, as in primary hyperparathyroidism or 
secondary to calcium deficiency, increases the 
rate of bone remodeling, and can result in loss of 
bone. In contrast, intermittent PTH elevation, as 
achieved by daily injections, cause bone gain 
and it is the only current bone anabolic therapy. 
High bone remodeling rates and bone loss with 
chronic PTH elevation is associated with 
excessive production of osteoclasts coupled to 
increased osteoblasts, with a negative balance 
between formation and resorption within each 
bone multicellular unit (BMU). Instead, the 
primary effect of intermittent PTH elevation is a 
rapid increase in osteoblasts and bone formation, 
attributed to the ability of PTH to promote 
proliferation of osteoblast precursors, to inhibit 
osteoblast apoptosis, to re-activate lining cells to 
become matrix synthesizing osteoblasts, or to a 
combination of these effects (1;2). Daily PTH 
injections in humans stimulate bone formation 
by increasing bone remodeling rate and the 
amount of bone formed by each remodeling unit, 
named “remodeling-based formation” (3). PTH 
also stimulates bone formation not coupled to 
prior resorption, referred to as “modeling-based 
formation”. However, the relative contribution 
of each of these mechanisms to the bone gain 
induced by PTH and the degree at which they 
operate in different bone surfaces remain unclear. 
Earlier work demonstrates that some of actions 
of PTH on the skeleton are mediated by direct 
effects of the hormone on osteocytes, the most 
abundant and highly communicated cells in bone 
(4). PTH downregulates the expression of the 
Sost gene, which encodes the potent inhibitor of 
bone formation sclerostin, expressed primarily in 
osteocytes in bone (5;6). PTH also increases the 
expression of FGF23, a hormone expressed in 
osteocytes (and osteoblasts) that regulates 
phosphate reabsorption in the kidney, 
contributing to mineral homeostasis (4;7;8). 
Moreover, the major skeletal effects of PTH are 
recapitulated in transgenic mice expressing a 
constitutively active PTH receptor in osteocytes, 
named DMP1-8kb-caPTHR1 mice (4;9-11). 
Thus, these mice display a marked increase in 
bone mineral density and increased bone 
formation rate (BFR) and osteoblasts in cortical 
and cancellous bone surfaces. In addition, 
expression of Sost/sclerostin is reduced and Wnt 
signaling is activated in DMP1-8kb-caPTHR1 
mice. Moreover, induction of Wnt target genes is 
abolished in double transgenic mice also 
expressing Sost in osteocytes (10). Furthermore, 
DMP1-8kb-caPTHR1 mice exhibit high bone 
resorption, as evidenced by elevated systemic 
levels of resorption markers, high number of 
osteoclasts in bone, and increased cortical bone 
porosity. In addition, circulating osteocalcin, an 
index of bone formation and remodeling, is also 
increased in DMP1-8kb-caPTHR1 mice.  
We have dissected herein the contribution of 
modeling-based bone formation and remodeling-
based bone formation, to the anabolic effect of 
PTH receptor signaling in osteocytes. Towards 
this end, we inhibited bone formation in DMP1-
8kb-caPTHR1 mice directly by generating 
double transgenic mice also overexpressing Sost 
in osteocytes; and we inhibited remodeling-
driven bone formation by blocking resorption 
with the bisphosphonate alendronate. Our 
findings demonstrate that PTH receptor 
signaling in osteocytes regulates bone mass 
through modeling-based and remodeling-based 
bone formation mechanisms that operate to a 
different extent in cortical and cancellous bone 
surfaces.  
EXPERIMENTAL PROCEDURES 
Generation of DMP1-8kb-caPTHR1 and 
DMP-Sost Transgenic Mice  
Generation of DMP1-8kb-caPTHR1 and DMP1-
8kb-Sost transgenic mice was described 
previously (9;10). Mice were born at the 
expected Mendelian frequency, were fertile, and 
exhibited normal size and weight. The genetic 
background of DMP1-8kb-caPTHR1 and 
DMP1-8kb-Sost mice is C57BL/6. Mouse 
colonies are maintained by breeding mice 
hemizygous for the transgene with wild type 
(WT) C57BL/6 mice. All transgenic mice used 
in these studies were hemizygous.  
DMP1-8kb-caPTHR1 mice were crossed with 
DMP1-8kb-Sost mice to obtain mice expressing 
the DMP1-8kb-caPTHR1 transgene mice 
expressing both the DMP1-8kb-caPTHR1 and 
the DMP1-8kb-Sost transgenes. Four-week-old 
3 
mice (n = 6–12 per group) were administered 
weekly subcutaneous injections of 16.1 
μmol/kg/week (5.25 mg/kg/week) of alendronate 
or the equivalent volume of saline, for 2 weeks. 
Mice were fed a regular diet (Harlan/Teklad 
7001) and water ad libitum and maintained on a 
12-h light/dark cycle. Protocols involving 
genetically modified mice and their WT 
littermates were approved by the Institutional 
Animal Care and Use Committees of Indiana 
University School of Medicine.  
Bone Turnover Markers  
Plasma osteocalcin (OCN) and C-telopeptide 
fragments of type I collagen (CTX) were 
measured using enzyme linked 
immunoadsorbent assays (Biomedical 
Technologies, Stoughton, MA, and 
Immunodiagnostic Systems Inc., Fountain Hills, 
AZ, respectively) following manufacturer’s 
instructions (10).  
Analysis of Skeletal Phenotypes 
BMD for the femora and the spine was 
determined by dual energy x-ray absorptiometry 
(DXA) using a PIXImus II densitometer (G.E. 
Medical Systems, Lunar Division, Madison, WI) 
as previously described (9). Mice were 
anesthetized via inhalation of 2.5% isoflurane 
(IsoFlo; Abbott laboratories, North Chicago, IL) 
mixed with O2 (1.5 liter/min). Radiographic 
images were obtained from anesthesized mice 
using a digital x-ray system, as previously 
published (9). For micro-CT analysis, bones 
were dissected, cleaned of soft tissue, stored in 
70% ethanol, and scanned at 6 micron resolution 
(Skyscan 1172, SkyScan, Kontich, Belgium). 
For histomorphometric analysis, femora and 
calvariae were dissected, fixed, and embedded in 
methyl methacrylate. Fluorochrome labeling of 
the bones was performed by intraperitoneal 
injections of calcein (30 mg/kg; Sigma Chemical 
Co, St. Louis, MO) and alizarin (50 mg/kg; 
Sigma Chemical Co) administered 7 and 2 days 
before sacrifice, respectively, as previously 
described (10). Thick cross-sections of 
undecalcified femora at the mid-diaphysis were 
prepared using a diamond embedded wire saw 
(Histosaw, Delaware Diamond Knives, 
Wilmington, DE) and ground to a final thickness 
of 30-35 μm. Frontal plane 8 μm-thick calvarial 
sections were obtained 2 mm anterior to the 
junction between fronto-parietal and sagittal 
sutures using an Automated Rotary Microtome 
Leica RM2255 (Leica Microsystems Inc., 
Bannockburn, IL). Sections were viewed at 20-
40 X magnification on a Leitz DMRXE 
microscope (Leica Mikroskopie und System 
GmbH, Wetzlar, Germany). Images were 
captured using a SPOT digital camera 
(Diagnostic Instruments, Inc., Sterling Heights, 
MI). Total, single, and double labeled perimeter, 
and inter-label width were measured on 
periosteal and endocortical surfaces of 2 femoral 
sections per mouse and on outer and inner 
periosteal surfaces of 1 calvarial section per 
mouse, using a semiautomatic analysis system 
(Bioquant OSTEO 7.20.10, Bioquant Image 
Analysis Co., Nashville, TN) attached to a 
microscope equipped with an ultraviolet light 
source (Nikon Optiphot 2 microscope, Nikon 
Instruments, Melville, NY). A combination of 
von Kossa followed by enzyme histochemistry 
for tartrate resistant acid phosphatase (TRAP) 
histochemistry was used to visualize mineralized 
bone and osteoclasts in calvarial sections. TRAP 
positive multinucleated cells were enumerated 
and the number was expressed per bone area. 
The terminology and units used are those 
recommended by the Histomorphometry 
Nomenclature Committee of the American 
Society for Bone and Mineral Research (12).  
Quantitative PCR 
Total RNA was extracted from ulnae from 6-
week-old mice using Ultraspec reagent (Biotecx 
Laboratories) according to the manufacturer’s 
instructions. Gene expression was analyzed by 
quantitative PCR as previously described  using 
primer probe sets from Applied Biosystems or 
from Roche Applied Science (9). Relative 
mRNA expression levels were normalized to the 
house-keeping gene ribosomal protein S2 using 
the ∆Ct method.  
Immunostaining 
Protein detection on paraffin-embedded tibiae 
was performed as previously described (10). 
Briefly, sections were deparaffinized, treated 
with 3% H2O2 to inhibit endogenous peroxidase 
activity, blocked with mouse, rabbit or goat 
serum, and then incubated with mouse anti-β-
catenin (BD Transduction Laboratories, San 
Jose, CA) (13) (14) or rabbit anti-phosphoSer133-
CREB (16) (Santa Cruz Biotechnology Inc, 
Santa Cruz, CA) with prior antigen retrieval 
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(DeCal Retrieval Solution, BioGenex, San 
Ramon, CA) and followed by signal 
amplification (ABC kit, Vector laboratories, 
Burlingame, CA). Corresponding non-immune 
IgGs were used as negative control. 
Statistical Analysis 
Data were analyzed using SigmaStat (SPSS 
Science, Chicago, IL). Differences between 
group means were evaluated using two-way 
ANOVA. All values are reported as the mean ± 
standard deviations (SD).  
RESULTS 
The increased bone remodeling exhibited by 
DMP1-8kb-caPTHR1 mice is regulated by 
Sost overexpression and alendronate 
treatment.  
DMP1-8kb-caPTHR1 transgenic mice exhibit 
high bone remodeling indicated by increased 
circulating levels of the resorption marker CTX 
and the formation marker osteocalcin (Figure 
1A and B). Double transgenic mice expressing 
both the caPTHR1 and Sost transgene in 
osteocytes exhibited even higher CTX levels 
than single DMP1-8kb-caPTHR1 transgenic 
mice (Figure 1A). And, alendronate decreased 
CTX levels in both DMP1-8kb-caPTHR1 mice 
and double transgenic mice. On the other hand, 
Sost overexpression markedly decreased 
circulating OCN in DMP1-8kb-caPTHR1 mice. 
Alendronate also decreased OCN levels in 
DMP1-8kb-caPTHR1 mice, but did not alter 
significantly the already low OCN of the double 
transgenic mice (Figure 1B). OCN is not only a 
bone formation marker but also a bone turnover 
marker because is released from the matrix to 
the circulation during resorption. However, low 
circulating OCN in the presence of elevated 
resorption is indicative of low bone formation 
rate and decreased osteoblast number. Thus, 
inhibition of Wnt signaling by Sost 
overexpression reduces bone formation, whereas 
alendronate administration blunts both 
resorption and formation.  
Consistent with increased remodeling, activation 
of the PTH receptor in osteocytes resulted in 
reduced bone material density, an index of tissue 
mineralization, measured by micro-CT in 
cortical and cancellous bone of the femur, in 
calvaria, as well as in vertebral cancellous bone 
(Figure 1C). The effects of Sost overexpression 
or bisphosphonate treatment were more evident 
in femoral cortical bone, but did not modify 
significantly bone material density in the other 
bones studied. In femoral cortical bone (mid-
diaphysis), Sost overexpression further 
decreased material density as it was lower in 
DMP1-8kb-caPTHR1; DMP1-8kb-Sost mice 
compared to DMP1-8kb-caPTHR1 mice, 
consistent with the increased resorption in the 
double transgenic mice compared to DMP1-8kb-
caPTHR1. In contrast, alendronate treatment led 
to increased bone material density in both 
DMP1-8kb-caPTHR1 and in double transgenic 
mice. These findings validate the genetic and 
pharmacological interventions chosen to inhibit 
directly bone formation or bone resorption-
driven bone formation, respectively, in DMP1-
8kb-caPTHR1 mice.  
Molecular mediators of PTH receptor action 
are differentially regulated by Sost 
overexpression and alendronate.  
The expression of osteoblast and osteoclast 
markers, as well as osteoclastogenic cytokines, 
was elevated in bones from DMP1-caPTHR1 
mice (Figure 2). Alkaline phosphatase, collagen 
1, and osteocalcin expression was increased in 
DMP1-caPTHR1 mice and reversed to wild type 
levels in DMP1-caPTHR1; DMP1-Sost double 
transgenic mice. Alendronate markedly blunted 
the expression of these genes in all mouse 
genotypes. In contrast, the expression of 
calcitonin receptor and TRAP was similarly high 
in single and double transgenic mice. Further, 
alendronate did not decrease the expression of 
these osteoclast markers, consistent with the 
evidence that inhibition of resorption by 
bisphosphonates results from direct blockade of 
osteoclast activity without decreasing osteoclast 
number, and even in some cases inducing 
accumulation of inactive osteoclasts (17-19). 
The increased expression of M-CSF exhibited by 
DMP1-caPTHR1 mice was not altered by Sost 
overexpression or bisphosphonate treatment. 
Sost overexpression led to an increase in 
RANKL expression compared to wild type mice 
and to a marked reduction in OPG expression in 
DMP1-caPTHR1 mice. These changes resulted 
in a RANKL/OPG ratio in double transgenic 
mice even higher than that of DMP1-caPTHR1 
mice. Alendronate treatment increased the 
expression of RANKL in all mouse genotypes, 
without inducing major changes in OPG. This 
5 
resulted in an overall increased RANKL/OPG 
ratio and in elimination of the effect of DMP1-
caPTHR1 transgene.   
DMP1-8kb-caPTHR1 mice exhibit activation 
of PTHR/cAMP and PTHR/Wnt signaling in 
osteocytes.   
Phosphorylated CREB (P-CREB), a direct 
downstream target of PTHR/cAMP signaling, 
and β-catenin, the canonical Wnt mediator, 
accumulated in the nuclei of osteocytes adjacent 
to both periosteal and endosteal surfaces of 
cortical bone of DMP1-caPTHR1 mice 
compared to WT littermates (Figure 3B/F and 
3A/E, respectively). Overexpresion of Sost did 
not affect P-CREB levels in either WT or 
DMP1-8kb-caPTHR mice (Figure 3C/D), 
whereas it reversed the increased β-catenin 
accumulation in osteocytes in double transgenic 
DMP1-8k-caPTHR;DMP1-Sost mice (Figure 
3H compared to 3F). In addition, β-catenin 
staining was also detected within cells covering 
the periosteal bone surface in bones from 
DMP1-caPTHR1 mice (Figure 3F, red arrows). 
In contrast, β-catenin staining was restricted to 
the membrane of osteoblasts on the periosteal 
surface in bone sections from double transgenic 
mice (Figure 3H). Thus, PTHR/cAMP and 
PTHR/Wnt signaling pathways are activated in 
all osteocytes, regardless of their proximity to 
periosteal or endosteal bone surfaces in mice 
with osteocytic activation of the PTHR. In 
addition, activation of PTHR signaling in 
osteocytes increases β-catenin accumulation not 
only in osteocytes but also in cells on the 
periosteal bone surface; and this effect is 
specifically prevented by Sost overexpression in 
double transgenic mice.  
Bone formation driven by osteocytic PTH 
receptor signaling on periosteal and 
endocortical surfaces of cortical bone is 
differentially regulated by Wnt signaling and 
resorption.  
The increased periosteal bone formation rate 
displayed by DMP1-8kb-caPTHR1 mice was 
reversed by Sost overexpression, due to a 
combination of decreased work of osteoblast 
teams (MAR) and reduced number of osteoblasts 
on bone surfaces (MS/BS) (Figure 4A). On the 
other hand, inhibition of resorption with 
alendronate did not affect periosteal bone 
formation in DMP1-8kb-caPTHR1 mice. In 
addition, alendronate did not alter significantly 
bone formation indexes in double transgenic 
mice, which were already low compared to the 
single DMP1-8kb-caPTHR1 transgenic mice. 
Therefore, bone formation induced by PTHR1 
signaling in osteocytes on the periosteal surface 
depends on the Wnt pathway but not on 
resorption.  
On the endocortical surface, Sost overexpression 
reduced equally BFR in wild type and in DMP1-
8kb-caPTHR1 mice. Thus, double transgenic 
DMP1-8kb-caPTHR1;DMP1-8kb-Sost mice still 
display higher BFR compared to DMP1-8kb-
Sost mice (Figure 4B). This lack of effect of 
Wnt inhibition on endocortical bone formation 
driven by osteocytic PTH receptor signaling 
resulted from a converse effect on MAR 
(increase) and on MS/BS (decrease) in the 
double transgenic mice. Similarly, inhibition of 
resorption reduced BFR in wild type and in 
DMP1-8kb-caPTHR1 mice and, as a 
consequence, in the group of animals treated 
with alendronate, transgenic mice still exhibited 
higher BFR than wild type littermates. However, 
the increase in MAR induced by osteocytic PTH 
receptor signaling was abolished by alendronate 
whereas MS/BS was decreased to a similar 
extent in both DMP1-8kb-caPTHR and wild 
type littermates. Resulting from the combination 
of low MS/BS induced by Sost overexpression 
and low MAR induced by alendronate, double 
transgenic mice treated with alendronate 
exhibited a BFR lower than wild type mice 
receiving vehicle. These results demonstrate that 
cooperation between Wnt activity and resorption 
drives bone formation on the endocortical 
surface of DMP1-8kb-caPTHR1 mice.  
Sost overexpression exacerbates and 
alendronate blunts resorption induced by 
PTH receptor activation in osteocytes.   
Sost overexpression further increased the already 
high intra-cortical remodeling observed in 
DMP1-8kb-caPTHR1 mice. This is 
demonstrated by increased porosity in the 
femoral midshaft and in the calvaria (Figure 5A 
and B). Furthermore, osteoclasts were markedly 
increased in calvaria from double transgenic 
mice (Figure 5C and D). Alendronate reduced 
femoral intra-cortical porosity, calvarial porosity, 
and osteoclast number in both DMP1-8kb-
caPTHR and double transgenic mice (Figure 
5A-D). Intra-cortical bone formation coupled to 
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resorption was high in calvaria from DMP1-
caPTHR1 mice and increased further in the 
double transgenic mice, and decreasing 
resorption with alendronate blunted these effects 
(Figure 5E). The reduction in bone formation is 
evidenced in the images of fluorochrome 
labeling, although quantification was not 
possible due to the intricate nature of the labels. 
Inhibition of Wnt signaling or resorption have 
opposite effects on bone mass and 
architecture in DMP1-8kb-caPTHR1 mice 
Long bones are more dense and femoral bone 
mineral density (BMD) is increased in DMP1-
8kb-caPTHR1 mice, and overexpression of Sost 
reverses these effects (Figure 6) (10). 
Alendronate increased BMD further in DMP1-
8kb-caPTHR mice; and it partially corrected the 
low BMD of DMP1-8kb-caPTHR1;DMP1-8kb-
Sost mice. As a result, double transgenic mice 
display bone mass undistinguishable from wild 
type littermates.  
In cortical bone of the femoral midshaft, DMP1-
8kb-caPTHR1 mice exhibit higher bone area and 
tissue area, increased cortical thickness, and 
elevated polar moment of inertia (Figure 7A and 
B). This is consistent with the increased 
periosteal bone formation shown in Figure 4A. 
Overexpression of Sost significantly reduced all 
these architectural parameters in the double 
transgenic mice. On the other hand, inhibition of 
bone remodeling with alendronate did not alter 
bone or tissue area, cortical thickness, or polar 
moment of inertia in DMP1-8kb-caPTHR1 mice, 
but reversed the effect of Sost overexpression in 
DMP1-8kb-caPTHR1;DMP1-8kb-Sost mice. 
In cancellous bone of the distal femur, the 
increase in bone volume and trabecular thickness 
and number, and the decrease in trabecular 
spacing observed in DMP1-8kb-caPTHR1 mice 
were also prevented by Sost overexpression 
(Figure 8A and B). Alendronate increased bone 
volume and trabecular number in wild type, 
DMP1-8kb-caPTHR1 as well as DMP1-8kb-
Sost mice. Moreover, the bisphosphonate 
reversed the decrease in bone volume and 
trabecular thickness in double transgenic mice, 
whereas it increased trabecular number to values 
similar of those of DMP1-8kb-caPTHR1 mice.  
Similar changes were found in the cancellous 
bone of the spine (Figure 9). The increase in 
BMD, bone volume, and trabecular thickness 
and number as well as the decrease in trabecular 
separation observed in lumbar vertebrae of 
DMP1-8kb-caPTHR1 mice were reversed in 
double transgenic mice, to values beyond those 
of single DMP1-8kb-Sost mice. Alendronate 
administration further increased spinal BMD and 
trabecular thickness in DMP1-8kb-caPTHR1 
mice; and increased bone mass in wild type 
littermates (Figure 9B and D). Furthermore, 
alendronate reversed the decrease in BMD, bone 
volume, trabecular thickness and number, and 
the increase in trabecular separation in double 
transgenic DMP1-8kb-caPTHR1;DMP1-8kb-
Sost mice.  
DISCUSSION 
This study dissected the contribution to bone 
gain induced by PTH receptor signaling, of 
modeling- versus remodeling-dependent 
mechanisms, and the degree at which they 
operate in cortical (periosteal and endosteal) and 
cancellous bone surfaces. 
Several aspects of our study are novel. We used 
DMP1-8kb-caPTHR1 transgenic mice 
expressing a constitutively active PTH receptor 
in osteocytes, a unique model that recapitulates 
the increased bone mass and remodeling induced 
by PTH elevation. Because bone formation is 
stimulated in all bone surfaces, this model 
presents an ideal opportunity to understand the 
mechanistic bases underlying the intricate 
actions of PTH in the skeleton. The approach of 
combining genetic and pharmacological 
interventions is also innovative and provides a 
powerful mechanistic insight because these 
manipulations inhibit bone formation by known 
mechanisms. Sost overexpression inhibits bone 
formation directly by antagonizing the Wnt 
pathway; and the bisphosphonate inhibits bone 
formation indirectly by stopping bone resorption. 
Our report provides mechanistic information of 
the events that control bone anabolism by 
systematic analysis at different tissue sublevels. 
We measured the amount of mineral or bone 
mineral density (BMD), the density of the 
mineral, the amount of bone, and its architectural 
distribution by micro-CT, and the rate at which 
osteoblasts produce bone by dynamic 
histomorphometry. Further, we have extended 
our study towards cellular and molecular levels 
by incorporating molecular analysis of genes 
that characterize osteoblasts and osteoclasts. We 
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have also investigated which intracellular 
pathways are activated by PTH signaling in the 
osteocytes (the cells that send the signals to the 
osteoblasts) and in the osteoblasts themselves 
(the cells that execute bone formation). In 
concert, all this information allowed us to 
advance our understanding on the mechanisms 
by which PTH induces bone anabolism in 
different bone compartments and surfaces. We 
show that direct inhibition of bone formation 
blocks completely PTH-induced formation on 
the periosteal surface of cortical bone and the 
gain in bone mass in cancellous bone. In contrast, 
inhibition of bone resorption did not alter bone 
formation on the periosteal surface of cortical 
bone, and it even potentiated the increase in 
bone mass and volume in cancellous bone, in 
both the appendicular and axial skeletons. 
Further, elevated bone formation on the 
endocortical surface was only completely 
reversed by the combination of inhibiting bone 
formation directly and indirectly by blocking 
bone resorption. We conclude that PTH receptor 
signaling in osteocytes regulates bone mass 
through modeling-based and remodeling-based 
bone formation mechanisms that operate to a 
different extent in cortical and cancellous bone 
surfaces.   
The effects of PTH on the skeleton are complex. 
Acting on cells of the osteoblastic lineage, PTH 
activates pathways that increase both bone 
resorption and formation (1;3;4). Depending on 
the duration and periodicity of the hormonal 
elevation, the balance between these two effects 
varies, leading to bone gain or loss on different 
bone envelops. However, the identity of the 
osteoblastic cells and the molecular mechanisms 
underlying PTH effects remain uncertain. Our 
previous findings that PTH receptor activation in 
osteocytes is sufficient to elicit both bone 
formation and bone resorption had pointed to 
osteocytes as crucial target cells of PTH skeletal 
actions (4;9;10). The current evidence shows 
that resorption influences bone formation 
differently depending on the bone compartment. 
The lack of inhibitory effect of alendronate on 
the elevated periosteal bone formation exhibited 
by DMP1-8kb-caPTHR1 mice is consistent with 
the fact that bone apposition on the periosteal 
surface is not a consequence of spatially-
associated previous bone resorption (20). In 
contrast, the increased periosteal bone formation 
is blocked completely by overexpressing Sost, 
suggesting that the effect depends on activation 
of Wnt signaling. These findings raise the 
possibility that the increase in periosteal bone 
formation associated with intermittent PTH 
administration to humans (21) or rodents (22) 
are due to hormonal actions on osteocytes. This 
stimulatory effect contrasts with the low 
periosteal bone formation exhibited by mice 
expressing the same constitutively active PTH 
receptor not only in osteocytes but also in pre-
osteoblasts and osteoblasts (driven by the 2.3kb 
fragment of the collagen1a1 promoter, 2.3-col1-
caPTHR1 mice) (23). The different outcomes 
might be a consequence of the purported direct 
inhibition of osteoblast differentiation in the 2.3-
col1-caPTHR1 mice (23;24), which evidently 
prevails over the stimulatory effect of activating 
the receptor in osteocytes. The increased versus 
decreased periosteal bone formation in mild 
versus severe chronic PTH elevation in humans 
(25) might be also a reflection of differential 
response to PTH by osteocytes versus 
osteoblasts. Osteocytes appear to express higher 
levels of PTH receptor than osteoblasts [(26) and 
Bellido et al, unpublished]. Thus, it is possible 
that lower circulating PTH levels could activate 
downstream signaling mainly in osteocytes 
whereas higher hormone levels would be 
required for activating the receptor also in 
osteoblasts. This scenario could explain the 
increase in periosteal bone formation with mild 
elevations of PTH and the decreased periosteal 
bone formation with severe elevation of the 
hormone.  
The current study shows that both PTHR/cAMP 
and PTHR/Wnt pathways are activated in 
osteocytes juxtaposed to periosteal as well as 
endosteal surfaces of cortical bone of DMP1-
caPTHR1 mice. However, bone formation 
induced by osteocytic caPTHR is driven by one 
or the other pathway depending on the bone 
surface. Our findings underscoring the 
importance of Wnt signaling for bone formation 
on the periosteal surface of cortical bone are 
consistent with evidence from mouse models 
with genetic manipulations leading to altered 
levels of Wnt inhibitors/antagonists. Mice 
expressing low levels (40-fold reduction in 
calvarial bone) of the Wnt sequestering 
antagonist secreted frizzle-related protein 4 
(SFRP4) exhibit increased periosteal bone 
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formation rate, without changes on the endosteal 
surface of cortical bone (27). The effect is due 
exclusively to higher mineralizing surface 
covered by osteoblasts (MS/BS), indicating that 
it results from stimulation of osteoblast 
differentiation and recruitment to the bone 
surface. Similarly, deletion of the Sost gene 
leads to marked increased periosteal (as well as 
endocortical) bone formation rate (28). In this 
latter case, however, both MS/BS as well as 
MAR are elevated, demonstrating that osteoblast 
activity is also stimulated. Consistently, 
overexpression of the Wnt antagonist Dkk1 in 
osteoblastic cells reduces cortical bone area and 
periosteal perimeter (29). Further, we show that 
DMP1-Sost transgenic mouse exhibit low 
vertebral cancellous bone, similar to previous 
reports describing mice overexpressing human 
Sost under the control of the murine osteocalcin 
(OG-2) promoter (30) or under the control of the 
regulatory regions of the Sost gene (31). Cortical 
bone of the femur is less affected as shown by 
Winkler et al (30) and in our own studies [(32) 
and the current manuscript]. In spite of the 
different effect of the Sost transgene by itself on 
cancellous versus cortical bone, Sost 
overexpression was equally effective in reducing 
the increased bone mass and volume induced by 
the DMP1-caPTHR1 transgene in both bone 
envelops. Moreover, although overexpression of 
Sost does not change the basal rate on bone 
formation, bone anabolism induced by 
mechanical stimulation on the periosteal surface 
is abrogated in mice overexpressing Sost in 
osteocytes, due to a reduction in both MS/BS 
and MAR (32). Taken together, these findings 
establish the requirement of Wnt signaling for 
bone formation on the periosteal surface of 
cortical bone.    
Remarkably, Wnt activation contributes 
differently to bone formation on the endosteal 
surface of cortical bone, as only the increased 
mineralizing surface is blocked by 
overexpressing Sost. In contrast, alendronate 
reduced mineral appositional rate demonstrating 
the importance of factors released during bone 
resorption. Complete reversion of bone 
formation induced by PTH signaling is only 
accomplished by simultaneous Sost 
overexpression and alendronate treatment. 
Therefore, there is cooperation between PTH-
induced Wnt activation and bone resorption, and 
these two effects impact specific functions of 
osteoblasts on the endosteal surface of cortical 
bone.  
The disorganized and exuberant bone formation 
exhibited in cancellous bone of DMP1-caPTHR1 
mice does not allow to measure bone formation 
rate in this envelop. Although BMD and micro-
CT analyses demonstrate that Sost 
overexpression abolished bone anabolism, 
whether this is due to direct inhibition of bone 
formation (modeling) or inhibition of resorption-
dependent bone formation (remodeling) is not 
possible to distinguish. Decreased bone mass 
and volume in Sost overexpressing mice could 
also result from exacerbated bone resorption. 
Indeed, osteoprotegerin (OPG), a recognized 
Wnt target gene (33-35), is markedly decreased 
in double transgenic DMP1-caPTHR1;DMP1-
8kb-Sost mice (10). And, RANKL expression is 
increased in osteoblastic cells derived from mice 
lacking β-catenin (35) as well as in bones from 
DMP1-8kb-Sost mice (10). Moreover, 
circulating CTX is further increased in the 
double transgenic mice compared to single 
DMP1-caPTHR1 mice (this report). In addition, 
although osteoclast number could not be 
accurately estimated in cancellous bone, the 
increased calvarial osteoclasts found in single 
DMP1-caPTHR mice were also further increased 
in double DMP1-caPTHR1;DMP1-8kb-Sost 
mice. These pieces of evidence indicate that 
activation of Wnt signaling by osteocytic PTH 
receptor restrains bone resorption, thus 
contributing to increasing bone mass in 
cancellous bone. Consistent with this notion, 
blockade of resorption with alendronate leads to 
further bone gain in the single and double 
transgenic mice.    
In conclusion, crosstalk between modeling-based 
bone formation and remodeling-based bone 
formation driven by PTH receptor signaling in 
osteocytes differentially contribute to bone gain 
in cortical and cancellous bone surfaces; and 
resorption is critical for full anabolism in cortical 
bone but tempers bone gain in cancellous bone 
(Figure 10). Understanding the mechanistic 
bases of PTH receptor action would allow 
dissecting anabolic versus resorptive effects and 
specifically trigger one action or the other at will, 
thus providing new opportunities for the 
treatment of bone diseases. 
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FIGURE LEGENDS 
FIGURE 1. The high bone remodeling exhibited by DMP1-8kb-caPTHR1 mice is blunted by 
alendronate. CTX (A) and OCN (B) were measured in plasma of 6.0-week-old DMP1-8kb-caPTHR1 
mice, with and without the DMP1-8kb-Sost transgene and with or without alendronate. (C) Bone 
material density (pixels) was measured in cortical bone of the femoral mid-diaphysis, calvaria, and 
cancellous bone of the distal femur and lumbar vertebrae by μCT. Bars represent the mean ± SD; n=9-
12 (A and B) and 4-5 (C) mice per group. *p<0.05 versus respective controls not expressing the 
caPTHR1 transgene and lines connect conditions with p<0.05, by two-way ANOVA. 
FIGURE 2. Molecular mediators of PTH receptor action are differentially regulated by Sost 
overexpression and alendronate. Gene expression was measured by quantitative PCR. Results are 
expressed relative to the housekeeping gene ribosomal protein S2. Bars represent mean ± SD of 3-7 
mice per group. *p<0.05 versus respective controls not expressing the caPTHR1 transgene and lines 
connect conditions with p<0.05, by two-way ANOVA. 
FIGURE 3. DMP1-8kb-caPTHR1 mice exhibit activation of PTHR/cAMP and PTHR/Wnt signaling 
in osteocytes. Expression of phosphoSer133-CREB (P-CREB, A-D) and β-catenin (E-H) was detected 
by immunohistochemistry in sections of tibial bone. Bone surfaces facing the periosteum (Periosteal 
Surface, PS) and the bone marrow (BM) and muscle fibers (M) are indicated. In some sections the 
bone is detached from the surrounding muscle or bone marrow tissue. Black arrows point to 
osteocytes labeled with anti-P-CREB (A-D) or anti-β-catenin (E-H) antibodies. Red arrows point to 
osteoblasts on the periosteal surface of bone labeled with anti-β-catenin antibody. Note that β-catenin 
is detected within the cells in the bone section from DMP1-8kb-caPTHR1 mice (F), but only in the 
cell membrane in the bone section from double transgenic DMP1-8kb-caPTHR1; DMP1-Sost mice 
(H). Bars indicate 10 µm.  
FIGURE 4.The increased periosteal bone formation induced by PTH receptor signaling in osteocytes 
depends on the Wnt pathway but not on resorption, whereas both Wnt signaling and resorption 
contribute to the high endocortical bone formation. Dynamic histomorphometric measurements were 
determined in the femur on the periosteal (A) and endocortical (B) surfaces in 3-5 mice per group. 
Bars represent the mean ± SD. *p<0.05 versus respective controls not expressing the caPTHR1 
transgene and lines connect conditions with p<0.05, by two-way ANOVA. 
FIGURE 5. Sost overexpression exacerbates and alendronate blunts resorption induced by PTH 
12 
receptor activation in osteocytes. Intracortical porosity in the femoral diaphysis was measured by 
micro-CT (A) and calvarial marrow space were calculated by measuring histomorphometrically the 
area occupied by marrow versus bone (B). Osteoclasts were quantified in TRAP stained calvarial 
sections. n=3-5 mice/group (C). Bars represent the mean ± SD. *p<0.05 versus respective controls not 
expressing the caPTHR1 transgene and lines connect conditions with p < 0.05, by two-way ANOVA. 
Representative images of histologic sections showing TRAP (+) osteoclasts (D) and fluorochome 
labeling (E) in the calvariae of 6.0-week-old WT and DMP1-8kb-caPTHR1 mice with or without the 
DMP1-8kb-Sost transgene or alendronate. Bars indicate 100 μm.  
FIGURE 6. The high femoral bone mass in DMP1-8kb-caPTHR1 mice depends on Wnt activation 
and is further increased by inhibiting bone resorption. Representative digital x-ray images of the 
hindlimb (A) and femoral BMD measured by DXA (B) in 6-week-old mice expressing the DMP1-
8kb-caPTHR1 and/or the DMP1-8kb-Sost transgenes or alendronate, and WT littermates is shown; 
n=9-12 mice per group. Bars represent the mean ± SD. *p<0.05 versus respective controls not 
expressing the caPTHR1 transgene and lines connect conditions with p<0.05, by two-way ANOVA. 
FIGURE 7. Changes in cortical bone geometry induced by PTH receptor signaling in osteocytes are 
abolished by Sost overexpression and this effect is counteracted by alendronate treatment. 
Representative images (A) and micro-CT cortical bone parameters (B) measured in the femoral mid-
diaphysis in the distal femur of 6-week-old mice expressing the DMP1-8kb-caPTHR1 and/or the 
DMP1-8kb-Sost transgenes or alendronate, and WT littermates. n=3-6 mice per group. Bars represent 
the mean ± SD. *p<0.05 versus respective controls not expressing the caPTHR1 transgene and lines 
connect conditions with p<0.05, by two-way ANOVA. 
FIGURE 8. Changes in volume and architecture in femoral cancellous bone of DMP1-8kb-caPTHR1 
mice are blocked by Sost overexpression and enhanced by alendronate treatment. Representative 
micro-CT images (A) and the cancellous bone parameters bone volume (BV/TV), and trabecular 
thickness (Tb. Th.), separation (Tb. Sp.), and number (Tb. N.) (B) measured by micro-CT in the distal 
femur of 6-week-old mice expressing the DMP1-8kb-caPTHR1 and/or the DMP1-8kb-Sost 
transgenes or alendronate, and WT littermates. n=4-5 mice per group. Bars represent the mean ± SD. 
*p<0.05 versus respective controls not expressing the caPTHR1 transgene and lines connect
conditions with p<0.05, by two-way ANOVA. 
FIGURE 9. Increased mass and volume and improved architecture of vertebral cancellous bone of 
DMP1-8kb-caPTHR1 mice depends on Wnt activation and is further enhanced by inhibiting bone 
resorption. (A) Representative micro-CT images of the 4th lumbar vertebrae. Lumbar spine BMD 
measured by DXA (B) and BV/TV, and Tb. Th., Tb. Sp., and Tb. N. measured by micro-CT (C) in 6-
week-old mice expressing the DMP1-8kb-caPTHR1 and/or the DMP1-8kb-Sost transgenes or 
alendronate, and WT littermates is shown; n=4-5 mice per group. Bars represent the mean ± SD. 
*p<0.05 versus respective controls not expressing the caPTHR1 transgene and lines connect
conditions with p<0.05, by two-way ANOVA. 
FIGURE 10. PTH receptor signaling in osteocytes and bone anabolism. Modeling-based bone 
formation and remodeling-based bone formation driven by PTH receptor signaling in osteocytes 
differentially contribute to bone gain in cortical and cancellous bone surfaces; and resorption is 
critical for full anabolism in cortical bone and tempers bone gain in cancellous bone. 
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Figure 9 
0 
10 
20 
30 
40 
50 
alendronate 
BV/TV 
pe
rc
en
t 
B 
D Tb. Th. 
0.00 
0.02 
0.04 
μm
 
alendronate alendronate 
Tb. N. 
0 
2 
4 
6 
8 
/m
m
 
alendronate 
Tb. Sp. 
0.0 
0.1 
0.2 
0.3 
μm
 
C 
g/
cm
2
0.00 
0.02 
0.04 
0.06 
alendronate 
spinal BMD 
* 
* 
* 
* 
* 
* 
* 
* 
* * * 
* 
* 
* 
* 
al
en
dr
on
at
e 
DMP1-caPTHR1 WT DMP1-caPTHR1; DMP1-SOST  DMP1-SOST 
ve
hi
cl
e 
A 
0.063 
* 
* 
* 
WT DMP1-caPTHR1 DMP1-Sost DMP1-caPTHR1; DMP1-Sost 
lumbar vertebra 
0.4 
 at Indiana U
niversity School of M
edicine on Septem
ber 9, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 10 
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